+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2026-2032- Product Image
GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2026-2032- Product Image
Sale

GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6120806
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The GalNAc-Oligonucleotide Conjugates Market is projected to reach USD 454.35 Million in 2026. It is expected to continue growing at a CAGR of 7.38%, reaching USD 685.84 Million by 2032.

GalNAc-Oligonucleotide Conjugates: Executive Overview

GalNAc-oligonucleotide conjugates are targeted nucleic-acid medicines that use N-acetylgalactosamine (GalNAc) ligands to promote uptake by the asialoglycoprotein receptor on hepatocytes. This design has supported subcutaneous administration, liver-focused delivery, and less frequent dosing for selected RNA interference and antisense applications. The field is shaped by advances in oligonucleotide chemistry, conjugate design, manufacturing, clinical development, and regulatory experience. Key considerations include durability of gene silencing, sequence specificity, hepatic safety, immunogenicity, formulation, and the ability to identify patients whose disease biology is addressable through liver-targeted modulation.

From Delivery Challenge to Targeted, Durable RNA Medicines

The landscape has shifted from treating oligonucleotides primarily as short-lived systemic molecules toward designing them as tissue-directed medicines. GalNAc conjugation has been particularly influential because receptor-mediated hepatocyte uptake can improve delivery efficiency and enable lower or less frequent dosing than many earlier approaches. This transformation has encouraged broader exploration of genetically validated targets, including pathways involved in lipid metabolism, liver disease, complement biology, and rare disorders.

Development is also becoming more integrated. Sequence selection, ligand valency, backbone chemistry, biomarker strategy, toxicology, and scalable conjugation processes increasingly need to be planned together. At the same time, developers face practical constraints: sequence-related off-target effects, class-specific adverse events, competition for validated targets, clinical endpoint complexity, and the need to demonstrate meaningful outcomes beyond molecular knockdown.

Artificial Intelligence Accelerates Sequence, Target, and Development Decisions

Artificial intelligence can contribute across the GalNAc-oligonucleotide development cycle by analyzing genomic, transcriptomic, structural, and clinical datasets. Machine-learning methods may help prioritize disease targets, identify conserved or disease-relevant RNA regions, assess potential off-target binding, and support optimization of chemical modifications and conjugate architectures. In discovery, these tools can narrow experimental libraries and improve the selection of candidates for hepatocyte uptake and durable activity.

The cumulative impact is most credible when AI is combined with laboratory and clinical validation. Models require high-quality, well-annotated datasets and can inherit biases from incomplete genomic diversity or inconsistent assay methods. Regulatory credibility therefore depends on traceable model development, reproducible validation, explainable decision criteria, and clear documentation of how computational outputs influence candidate selection, safety assessment, manufacturing controls, and clinical trial design.

Regional Dynamics Reflect Science, Regulation, and Manufacturing Readiness

North America combines substantial biotechnology capabilities, advanced clinical infrastructure, and extensive experience with nucleic-acid therapeutics. Europe supports translational research through sophisticated academic and clinical networks, while regulatory and health-technology-assessment requirements place strong emphasis on evidence quality, long-term safety, and demonstrated patient benefit. Asia-Pacific is strengthened by major pharmaceutical, biotechnology, and manufacturing ecosystems, with Japan, China, South Korea, and Australia each contributing distinct research, regulatory, and clinical capabilities.

Latin America presents opportunities linked to specialist centers and growing interest in advanced medicines, alongside challenges involving reimbursement, logistics, and access to genomic testing. The Middle East is developing research and healthcare capacity unevenly, with selected countries investing in precision medicine and specialized infrastructure. Africa remains diverse in research readiness and healthcare access; partnerships, local capacity building, adaptable trial models, and attention to genetic diversity are important for responsible participation in development and eventual deployment.

Economic and Security Groupings Shape Collaboration and Access

ASEAN economies offer a varied combination of manufacturing potential, clinical-trial capacity, and expanding biotechnology activity, but regulatory harmonization and cross-border execution remain important priorities. BRICS members span major scientific, pharmaceutical, and patient populations, creating opportunities for collaboration while also requiring careful navigation of different standards, procurement systems, and intellectual-property environments. The European Union benefits from coordinated scientific and regulatory structures, although market-access decisions remain influenced by national health systems.

The G7 provides concentrated expertise in advanced therapeutics, translational science, and regulatory practice, while NATO countries collectively represent extensive biomedical infrastructure and established research networks. GCC states are investing in healthcare modernization, specialized treatment centers, and life-science capabilities. Across these groups, successful development depends on interoperable data, aligned clinical standards, technology transfer, skilled workforces, and equitable access planning rather than on scientific capability alone.

Country-Level Capabilities Are Uneven but Complementary

The United States and Canada contribute strong discovery, clinical, and regulatory ecosystems, while the United Kingdom, France, Germany, Italy, and Spain provide important European research, specialist-care, and manufacturing capabilities within broader regional frameworks. Australia adds high-quality clinical research and biotechnology expertise. Japan is notable for advanced pharmaceutical science and a mature healthcare system; China has substantial biomedical investment, manufacturing depth, and a large clinical environment; and South Korea combines biopharmaceutical manufacturing with growing platform-technology capabilities.

India contributes expanding pharmaceutical, chemistry, and clinical capacity, while Brazil and Mexico are important Latin American markets with specialist institutions and large, diverse patient populations. Russia retains scientific and pharmaceutical capabilities but operates within a complex external environment affecting collaboration and supply chains. Across all listed countries, priorities include validated biomarkers, specialist training, consistent regulatory pathways, reliable cold-chain and laboratory capacity where needed, and inclusion of populations that are often underrepresented in genetic and clinical datasets.

Prioritize Translational Evidence, Scalable Manufacturing, and Equitable Access

Industry leaders should focus portfolios on targets with strong human genetic or mechanistic validation and define clinically meaningful endpoints early. Candidate selection should integrate sequence specificity, hepatocyte uptake, durability, immunogenicity, hepatic safety, dosing convenience, and the feasibility of companion diagnostic or biomarker strategies. Early consultation with regulators and clinical experts can clarify expectations for long-term follow-up, pharmacodynamic evidence, and risk management.

Manufacturing teams should establish robust controls for oligonucleotide synthesis, GalNAc attachment, impurity profiles, analytical characterization, and batch consistency. Organizations should also build AI governance around data provenance, independent validation, human oversight, and auditability. Finally, access planning should begin during development: trial networks should reflect relevant patient diversity, and launch strategies should address diagnostic capacity, specialist administration, reimbursement evidence, and supply continuity across high-resource and emerging healthcare systems.

Methodology: Triangulating Scientific, Clinical, Regulatory, and Regional Evidence

This executive summary uses a structured qualitative synthesis of publicly verifiable evidence relevant to GalNAc-mediated oligonucleotide delivery. The assessment framework covers peer-reviewed research, clinical-trial records, regulatory materials, scientific-conference disclosures, manufacturing and analytical literature, and documented healthcare-system characteristics. Evidence is organized around delivery biology, chemistry, therapeutic application, safety, development practice, regional infrastructure, and policy context.

Findings are interpreted through triangulation rather than a single source. Scientific claims are compared with clinical and regulatory evidence where available, while regional, group, and country observations are limited to documented capabilities or structural conditions. The analysis avoids unsupported quantitative claims and does not infer performance, access, or readiness solely from the presence of research activity. Because the field evolves rapidly, conclusions should be refreshed as clinical readouts, regulatory decisions, safety findings, and manufacturing standards develop.

The Field’s Next Advantage Will Come From Execution as Much as Biology

GalNAc-oligonucleotide conjugates have established a powerful framework for liver-directed nucleic-acid therapeutics, but continued progress depends on disciplined translation. Durable pharmacology must be matched with convincing clinical benefit, well-characterized safety, reproducible manufacturing, and practical delivery through real healthcare systems. Artificial intelligence can improve prioritization and efficiency, yet it cannot replace experimental validation, transparent governance, or patient-centered evidence.

Leaders that connect target biology, conjugate chemistry, clinical strategy, regulatory planning, manufacturing quality, and access considerations early will be better positioned to convert platform capability into durable therapeutic value. Regional partnerships and inclusive evidence generation will be especially important as development expands beyond established research centers.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. GalNAc-Oligonucleotide Conjugates Market, by Product Type
7.1. Introduction
7.2. Antisense Oligonucleotides
7.3. Aptamers
7.4. MiRNA
7.5. SiRNA
8. GalNAc-Oligonucleotide Conjugates Market, by Therapeutic Application
8.1. Introduction
8.2. Infectious Diseases
8.3. Metabolic Disorders
8.4. Oncology
8.5. Rare Diseases
9. GalNAc-Oligonucleotide Conjugates Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
9.3.1. Clinical Stage
9.3.2. Preclinical Stage
10. GalNAc-Oligonucleotide Conjugates Market, by End User
10.1. Introduction
10.2. Biotechnology Companies
10.3. Contract Research Organizations
10.4. Pharmaceutical Companies
10.4.1. Large Pharma
10.4.2. Small Pharma
11. GalNAc-Oligonucleotide Conjugates Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Distributors
11.4. Offline
11.5. Online
12. GalNAc-Oligonucleotide Conjugates Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. GalNAc-Oligonucleotide Conjugates Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. GalNAc-Oligonucleotide Conjugates Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Akcea Therapeutics, Inc.
16.2. Alnylam Pharmaceuticals, Inc.
16.3. Amgen Inc.
16.4. Arcturus Therapeutics Holdings Inc.
16.5. Arrowhead Pharmaceuticals, Inc.
16.6. AstraZeneca plc
16.7. Beam Therapeutics Inc.
16.8. BioNTech SE
16.9. CureVac N.V.
16.10. Eli Lilly and Company
16.11. Gilead Sciences, Inc.
16.12. GlaxoSmithKline plc
16.13. Ionis Pharmaceuticals, Inc.
16.14. Merck & Co., Inc.
16.15. Moderna, Inc.
16.16. Novartis AG
16.17. Novo Nordisk A/S
16.18. Pfizer Inc.
16.19. Regeneron Pharmaceuticals, Inc.
16.20. Roche Holding AG
16.21. Sanofi S.A.
16.22. Sarepta Therapeutics, Inc.
16.23. Takeda Development Center Americas, Inc.
16.24. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global GalNAc-Oligonucleotide Conjugates Market, Years Considered for the Study
FIGURE 2. Global GalNAc-Oligonucleotide Conjugates Market, Research Design
FIGURE 3. Global GalNAc-Oligonucleotide Conjugates Market, Research Framework
FIGURE 4. Global GalNAc-Oligonucleotide Conjugates Market, Data Triangulation
FIGURE 5. Global GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
FIGURE 6. Global GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2025 vs 2032 (%)
FIGURE 9. Global GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 11. Global GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global GalNAc-Oligonucleotide Conjugates Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global GalNAc-Oligonucleotide Conjugates Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global GalNAc-Oligonucleotide Conjugates Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global GalNAc-Oligonucleotide Conjugates Market Segmentation & Coverage
TABLE 2. Global GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 3. Global GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Antisense Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antisense Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antisense Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Aptamers Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Aptamers Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Aptamers Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global MiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global MiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global MiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global SiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global SiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global SiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 17. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Rare Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Rare Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Rare Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 30. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Clinical Stage Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Clinical Stage Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Clinical Stage Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Preclinical Stage Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Preclinical Stage Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Preclinical Stage Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 43. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Large Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Large Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Large Pharma Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Small Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Small Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Small Pharma Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 59. Global Direct Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Direct Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Direct Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Distributors Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Distributors Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Distributors Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. North America GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. North America GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 82. North America GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 83. North America GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 84. North America GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 85. North America GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. North America GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 87. North America GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 90. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 91. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 92. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 93. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 95. Latin America GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Europe GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Europe GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 98. Europe GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 99. Europe GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 100. Europe GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 101. Europe GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Europe GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 103. Europe GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 106. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 107. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 108. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 109. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 111. Middle East GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. Africa GalNAc-Oligonucleotide Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Africa GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 114. Africa GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 115. Africa GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 116. Africa GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 117. Africa GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. Africa GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 119. Africa GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. Global GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 124. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 125. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 126. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 128. ASEAN GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. GCC GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. GCC GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 131. GCC GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 132. GCC GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 133. GCC GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 134. GCC GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. GCC GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 136. GCC GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. European Union GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. European Union GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 139. European Union GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 140. European Union GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 141. European Union GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 142. European Union GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. European Union GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 144. European Union GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 148. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 149. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 150. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 152. BRICS GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. G7 GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. G7 GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 155. G7 GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 156. G7 GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 157. G7 GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 158. G7 GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. G7 GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 160. G7 GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. NATO GalNAc-Oligonucleotide Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. NATO GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. NATO GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 164. NATO GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 165. NATO GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 166. NATO GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. NATO GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 168. NATO GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Global GalNAc-Oligonucleotide Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. United States GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 171. United States GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 172. United States GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 173. United States GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 174. United States GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 175. United States GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. United States GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 177. United States GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Canada GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 179. Canada GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. Canada GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 181. Canada GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 182. Canada GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 183. Canada GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Canada GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 185. Canada GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. Mexico GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 187. Mexico GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 188. Mexico GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 189. Mexico GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 190. Mexico GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 191. Mexico GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. Mexico GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 193. Mexico GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Brazil GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 195. Brazil GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 196. Brazil GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 197. Brazil GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 198. Brazil GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 199. Brazil GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Brazil GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 201. Brazil GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 203. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 204. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 205. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 206. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 207. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 209. United Kingdom GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. Germany GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 211. Germany GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 212. Germany GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 213. Germany GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 214. Germany GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 215. Germany GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. Germany GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 217. Germany GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. France GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 219. France GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 220. France GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 221. France GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 222. France GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 223. France GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. France GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 225. France GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Russia GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 227. Russia GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 228. Russia GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 229. Russia GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 230. Russia GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 231. Russia GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Russia GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 233. Russia GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Italy GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 235. Italy GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. Italy GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 237. Italy GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 238. Italy GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 239. Italy GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Italy GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 241. Italy GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. Spain GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 243. Spain GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 244. Spain GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 245. Spain GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 246. Spain GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 247. Spain GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Spain GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 249. Spain GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. China GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 251. China GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 252. China GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 253. China GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 254. China GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 255. China GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. China GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 257. China GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. India GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 259. India GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 260. India GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 261. India GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 262. India GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 263. India GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. India GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 265. India GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Japan GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 267. Japan GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 268. Japan GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 269. Japan GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 270. Japan GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 271. Japan GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Japan GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 273. Japan GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. Australia GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 275. Australia GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 276. Australia GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 277. Australia GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 278. Australia GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 279. Australia GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. Australia GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 281. Australia GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. South Korea GalNAc-Oligonucleotide Conjugates Market Size, 2017-2032 (USD Million)
TABLE 283. South Korea GalNAc-Oligonucleotide Conjugates Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 284. South Korea GalNAc-Oligonucleotide Conjugates Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 285. South Korea GalNAc-Oligonucleotide Conjugates Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 286. South Korea GalNAc-Oligonucleotide Conjugates Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 287. South Korea GalNAc-Oligonucleotide Conjugates Market Size, by End User, 2017-2032 (USD Million)
TABLE 288. South Korea GalNAc-Oligonucleotide Conjugates Market Size, by Pharmaceutical Companies, 2017-2032 (USD Million)
TABLE 289. South Korea GalNAc-Oligonucleotide Conjugates Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 290. Global GalNAc-Oligonucleotide Conjugates Market Share, by Key Player, 2025
TABLE 291. Global GalNAc-Oligonucleotide Conjugates Market, Key Experts

Companies Mentioned

  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CureVac N.V.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

GalNAc-ASO Conjugates Market - Global Forecast 2026-2032 - Product Image

GalNAc-ASO Conjugates Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
GalNAc-siRNA Conjugates Market - Global Forecast 2026-2032 - Product Image

GalNAc-siRNA Conjugates Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Oligonucleotide Conjugate Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Oligonucleotide Conjugate Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 181 Pages
  • Global
From
Subcutaneous Biologics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Subcutaneous Biologics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
siRNA Conjugate Market Report: Trends, Forecast and Competitive Analysis to 2035 - Product Image

siRNA Conjugate Market Report: Trends, Forecast and Competitive Analysis to 2035

  • Report
  • 255 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.